Network pharmacology based study on mechanism of peony leaf in the treatment of cervical cancer

Abstract

Abstract:ObjectiveTo analyze the multicomponent, multitarget and multipathway mechanism of peony leaf in the treatment of cervical cancer based on network pharmacology. MethodsThe possible active components and targets in peony leaf were screened and predicted by pharmacological database and analysis platform of traditional Chinese medicine system, and the related targets of cervical cancer diseases were obtained by searching Therapeutic Target Database and others. The potential targets for the disease regulation were screened according to the active components of peony leaves entering blood, then the key target names and the pathways involved in the treatment of peony leaf were selected according to the network topological characteristic parameters. Then, the enrichment analysis was carried out by using ClueGO software plugin. ResultsThere were 194 target sites for 11 blood entry components in peony leaves. Finally, 171 signal pathways were obtained, and 21 key pathways related to cervical cancer were obtained after the wide pathway was excluded, such as estrogen signaling pathway, neurotrophin signaling pathway and so on. ConclusionPeony leaves may play a vital role in the treatment of cervical cancer by acting on inflammatory, metabolic, immunological, endocrine and cell cycle related protein targets and pathways.

Key words:Uterine cervical neoplasms,Signal transduction,Network pharmacology,Peony leaf

Du Jingquan*, Guo Xiaoling, Wei Yongli, Li Keming, Yu Hao. Network pharmacology based study on mechanism of peony leaf in the treatment of cervical cancer[J]. Journal of International Oncology, 2018, 45(8): 519-524.

References

［1］陈万青, 郑荣寿, 张思维, 等. 2012年中国恶性肿瘤发病和死亡分析［J］. 中国肿瘤, 2016, 25(1): 18. DOI: 10.11735/j.issn.10040242.2016.01.A001. ［2］单玮, 张涛, 张铁军, 等. 我国女性人乳头瘤病毒(HPV)感染的流行病学现状［J］. 中华疾病控制杂志, 2017, 21(1): 8993. DOI: 10.16462/j.cnki.zhjbkz.2017.01.021. ［3］ Vesco KK, Whitlock EP, Eder M, et al. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force［J］. Ann Intern Med, 2011, 155(10): 698705. DOI: 10.7326/000348191551020111115000377. ［4］陈旭豪, 任汐鹰, 江路, 等. 香港HPV疫苗接种现状以及对我国内地宫颈癌一级预防的借鉴作用［J］. 现代妇产科进展, 2018, 27(1): 6467, 71. DOI: 10.13283/j.cnki.xdfckjz.2018.01.016. ［5］国家药典委员会. 中华人民共和国药典: 2010年版［M］. 北京: 中国医药科技出版社, 2010: 160. ［6］王斌利, 王新娣, 董颖, 等. 牡丹的食药价值研究进展［J］. 甘肃医药, 2017, 36(2): 9698. DOI: 10.15975/j.cnki.gsyy.2017.02.005. ［7］张彦琼, 李梢. 网络药理学与中医药现代研究的若干进展［J］. 中国药理学与毒理学杂志, 2015, 29(6): 883892. DOI: 10.3867/j.issn.10003002.2015.06.002. ［8］ Li Y, Zhang J, Zhang L, et al. Systems pharmacology to decipher the combinational antimigraine effects of Tianshu formula［J］. J Ethnopharmacol, 2015, 174: 4556. DOI: 10.1016/j.jep.2015.07.043. ［9］ Liu H, Wang J, Zhou W, et al. Systems approaches and polypharmacology for drug discovery from herbal medicines: an example using licorice［J］. J Ethnopharmacol, 2013, 146(3): 773793. DOI: 10.1016/j.jep.2013.02.004. ［10］ Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine［J］. Pharmacol Rev, 2011, 63(2): 437459. DOI: 10.1124/pr.110.003533. ［11］ Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plugin to decipher functionally grouped gene ontology and pathway annotation networks［J］. Bioinformatics, 2009, 25(8): 10911093. DOI: 10.1093/bioinformatics/btp101. ［12］汝锦龙. 中药系统药理学数据库和分析平台的构建和应用［D］. 咸阳: 西北农林科技大学, 2015. ［13］ Martin A, Ochagavia ME, Rabasa LC, et al. BisoGenet: a new tool for gene network building, visualization and analysis［J］. Bmc Bioinformatics, 2010, 11: 91. DOI: 10.1186/147121051191. ［14］郑春丽. 基于靶点网络的中药复方协同整合作用机制研究［D］. 咸阳: 西北农林科技大学, 2017. ［15］胡南, 许惠玉, 陈志伟, 等. 芍药苷的药理学研究进展［J］. 齐齐哈尔医学院学报, 2007, 28(9): 10931095. DOI: 10.3969/j.issn.10021256.2007.09.045. ［16］孙丽荣, 曹雄, 侯凤青, 等. 芍药苷研究进展［J］. 中国中药杂志, 2008, 33(18): 20282032. DOI: 10.3321/j.issn:10015302.2008.18.004. ［17］ Zheng NG, Mo SJ, Li JP, et al. AntiCSC effects in human esophageal squamous cell carcinomas and Eca109/9706 cells induced by nanoliposomal quercetin alone or combined with CD 133 antiserum.［J］. Asian Pac J Cancer Prev, 2014, 15(20): 86798684. ［18］王莉, 杨永杰, 陈松华, 等. β谷甾醇对子宫颈癌细胞微管系统的影响［J］. 中华医学杂志, 2006, 86(39): 27712775. DOI: 10.3760/j:issn:03762491.2006.39.007. ［19］张伟. 儿茶酚胺通过调控β2ARSIRT1p53信号通路诱导宫颈癌细胞化疗药物抵抗［D］. 开封: 河南大学, 2013. DOI: 10.7666/d.D371557. ［20］李新敏, 潘晓琳. p53 codon 72多态性与宫颈癌发生机制的研究［J］. 国际肿瘤学杂志, 2006, 33(9): 695697. DOI: 10.3760/cma.j.issn.1673422X.2006.09.017. ［21］段海霞, 李东红, 暴蕾, 等. NFκB信号通路介导楤木皂甙抗宫颈癌作用及机制研究［J］. 重庆医学, 2017, 46(7): 889891. DOI: 10.3969/j.issn.16718348.2017.07.008. ［22］罗守军. 宫颈癌患者外周血中IL6、IL8和IL17的表达及临床意义［J］. 中国妇幼保健, 2015, 30(13): 19971998. DOI: 10.7620/zgfybj.j.issn.10014411.2015.13.10. ［23］王立岩, 许晓艳, 盛敏佳, 等. HIF1α及VEGF在宫颈癌组织中的表达及其临床意义［J］. 中国实验诊断学, 2009, 13(12): 17491752. DOI: 10.3969/j.issn.10074287.2009.12.033. ［24］周琴, 杨小姣, 石孟琼, 等. 南赤瓟醇提物通过PI3K/Akt/mTOR信号通路促进人宫颈癌Caski细胞凋亡［J］. 中国临床药理学与治疗学, 2016, 21(1): 4249. ［25］张惠娇, 李玲, 沈洪武, 等. CerbB2、P53和Ki67在宫颈癌的表达及其临床意义［J］. 齐齐哈尔医学院学报, 2006, 27(2): 131133. DOI: 10.3969/j.issn.10021256.2006.02.002. ［26］金云峰, 奚庆华, 黄国琴, 等. 转录因子FOXO1在宫颈癌中的表达及意义［J］. 江苏医药, 2016, 42(13): 14561459, 封3. DOI: 10.19460/j.cnki.02533685.2016.13.011. ［27］史梦婕, 邵松军, 李洁媚, 等. Hippo通路与肿瘤相关性研究进展［J］. 中国细胞生物学学报, 2014, 36(3): 361365. DOI: 10.11844/cjcb.2014.03.0267. ［28］ Hua FF, Liu SS, Zhu LH, et al. MiRNA3383p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway［J］. Eur Rev Med Pharmacol Sci, 2017, 21(23): 53425352. DOI: 10.26355/eurrev_201712_13919. ［29］刘臣彪, 陈昌杰, 章尧. 神经营养素及其受体与肿瘤的相关性和作用的研究进展［J］. 实用癌症杂志, 2007, 22(4): 425427. DOI: 10.3969/j.issn.10015930.2007.04.037. ［30］罗丽丽, 程欣, 蔡红兵. TGFβ1的表达、HPV16 E7基因多态性与宫颈癌的相关性［J］. 武汉大学学报(医学版), 2014, 35(4): 507510. DOI: 10.14188/j.16718852.2014.04.024. ［31］冀静, 刘海娟, 宁芬茹, 等. Sox2通过Wnt信号通路对宫颈癌侵袭及迁移能力的影响［J］. 西安交通大学学报(医学版), 2016, 37(2): 230233. DOI: 10.7652/jdyxb201602017. ［32］郑旭琴, 孙敏, 刘超. 催乳素与人类肿瘤关系的新认识［J］. 国外医学(内分泌学分册), 2004, 24(2): 111113. DOI: 10.3760/cma.j.issn.16734157.2004.02.014. ［33］王金桃, 王志敏, 丁玲, 等. 雌激素及雌激素α受体Xba Ⅰ和PvuⅡ基因多态性与宫颈癌关系的研究［J］. 中华肿瘤防治杂志, 2011, 18(10): 746749. DOI: 10.16073/j.cnki.cjcpt.2011.10.008. ［34］胡东昊, 王乔新, 牛海燕, 等. 基质细胞衍生因子1、人绒毛膜促性腺激素β亚基及基质金属蛋白酶2的表达与宫颈癌分期与预后的相关性研究［J］. 中国性科学, 2016, 25(2): 4850. DOI: 10.3969/j.issn.16721993.2016.02.016. ［35］吴晓明, 牛海杰, 吴艳芳, 等. 晚期癌症患者血清甲状腺素水平的变化及其临床预后价值［J］. 中国肿瘤临床与康复, 2005, 12(5): 385387. DOI: 10.13455/j.cnki.cjcor.2005.05.001. ［36］张霞, 刘建英. AGEsRAGE系统与二甲双胍抗肿瘤作用研究进展［J］. 中国新药杂志, 2014, 23(4): 441444. ［37］高峻. 宫颈癌患者外周血调节性B细胞亚群的检测及临床意义［J］. 中国社区医师(医学专业), 2011, 13(16): 227228. DOI: 10.3969/j.issn.1007614x.2011.16.220. ［38］姜鹏, 胡云辉, 古丽娜·库尔班, 等. 新疆Ⅱ、Ⅲ期宫颈癌患者外周血T细胞亚群、B细胞、NK细胞分析［J］. 重庆医学, 2015, 44(34): 47964798. DOI: 10.3969/j.issn.16718348.2015.34.015. ［39］李秉枢, 付琼, 程艳香, 等. 丹皮酚协同顺铂抗人宫颈鳞癌SiHa细胞及其机制［J］. 肿瘤学杂志, 2010, 16(11): 845848.

[1]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[2]	Zhang Lu, Jiang Hua, Lin Zhou, Ma Chenying, Xu Xiaoting, Wang Lili, Zhou Juying.Analysis of curative effect and prognosis of immune checkpoint inhibitor in the treatment of recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2023, 50(8): 475-483.
[3]	Lyu Lu, Sun Pengfei.Gut flora and cervical cancer[J]. Journal of International Oncology, 2023, 50(6): 373-376.
[4]	Ma Xueyan, Lu Lili, Sun Pengfei.Advances in the immune microenvironment in cervical cancer[J]. Journal of International Oncology, 2023, 50(1): 47-50.
[5]	Zhang Lu, Zhou Juying, Ma Chenying, Lin Zhou.Advances in immunotherapy for recurrent and metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 517-520.
[6]	Shi Yingxia, Hu Lijun, Yu Jingping.Application of immune checkpoint inhibitors in the treatment of recurrent or metastatic cervical cancer[J]. Journal of International Oncology, 2022, 49(9): 568-571.
[7]	Peng Chen, Xie Yintong, Zhang Xin, Xie Peng.Research progress of maintenance therapy for cervical cancer[J]. Journal of International Oncology, 2022, 49(7): 430-435.
[8]	Yuan Chenyang, Zhou Juying.Research progress on prognostic factors of cervical cancer[J]. Journal of International Oncology, 2022, 49(5): 307-313.
[9]	Wang Yue, Wu Qiong, Xu Yuan, Gong Wei, Xu Xiaoting.Screening and treatment progression of elderly cervical cancer[J]. Journal of International Oncology, 2022, 49(12): 754-758.
[10]	Ma Xiuzhen, Lu Yan, Zhao Bingbing, Qiu Hongcong, Xu Xun, Wei Min.Effects of total flavonoids from Baeckea frutescens on the migration, invasion and apoptosis of cervical cancer SiHa cells[J]. Journal of International Oncology, 2021, 48(4): 206-211.
[11]	Yu Mingyue, Chen Zhengzheng, Zhao Xuxu, Ren Pingping, Zhang Ying, Ge Li, Zhu Meiling, Zhao Weidong.Factors related to postoperative adjuvant therapy of locally advanced cervical cancer and building of a nomogram prediction model[J]. Journal of International Oncology, 2021, 48(1): 35-40.
[12]	Ding Xuchao, Cao Lili.Common active targeting nano drug delivery systems for cervical cancer[J]. Journal of International Oncology, 2021, 48(1): 61-64.
[13]	Shu Hang, Xu Zhonghua, Zhu Haochen, Yang Yahui, Lyu Yin.Research progress of radiosensitivity in cervical cancer[J]. Journal of International Oncology, 2020, 47(8): 496-500.
[14]	Song Mingze, Cheng Yiming, Li Gang, Wang Zhenming, Li Shirong.Value of P16/Ki-67 double staining detection in screening cervical cancer and precancerous lesions[J]. Journal of International Oncology, 2020, 47(11): 675-681.
[15]	Li Ang, Wei Fang.Current status and future challenges of HPV preventive vaccine of cervical cancer[J]. Journal of International Oncology, 2019, 46(5): 307-310.